[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.145.176.252. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
February 22, 2006

Adamantane Resistance in Influenza A

Author Affiliations
 

Author Affiliations: Division of Infectious Diseases (Drs Weinstock and Zuccotti) and Division of Blood and Marrow Transplantation (Dr Weinstock), Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY. Dr Zuccotti is also Contributing Editor, JAMA.

 

Published online February 2, 2006 (doi:10.1001/jama.295.8.jed60009).

JAMA. 2006;295(8):934-936. doi:10.1001/jama.295.8.jed60009

The global burden of influenza infection is staggering. In a typical year, approximately 20% of the world's population is infected and more than a half million individuals die of influenza-associated complications.1 During influenza pandemics, morbidity and mortality are catastrophic—20 million to 100 million individuals died in the 1918 influenza pandemic, 2 million in the 1955 pandemic, and 1 million in the 1968 pandemic.2

First Page Preview View Large
First page PDF preview
First page PDF preview
×